Vergent plans to use the funding to advance the development of the company’s fluorescent tumor imaging agent VGT-309. Initially, VGT-309 will be used to illuminate lung cancer tumors, according to the Oct. 4 Vergent news release.
Orlando Health Ventures led the funding round. This funding round brings Vergent’s total capital raised to $34 million.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
